carmustine has been researched along with Tumour Lysis Syndrome in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "First relapse was treated with high-dose BEAM chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT)." | 1.30 | Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation. ( Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fetscher, S | 1 |
| Lübbert, M | 1 |
| Kanz, L | 1 |
| Behringer, D | 1 |
| Finke, J | 1 |
| Mertelsmann, R | 1 |
| Lange, W | 1 |
1 other study available for carmustine and Tumour Lysis Syndrome
| Article | Year |
|---|---|
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 1997 |